Acute Decompensated Heart Failure (ADHF) | Norton Healthcare

Indication: Acute Decompensated Heart Failure (ADHF)

A multicenter, randomized, double-blind, double-dummy, parallel group, active controlled 8-week study to evaluate the effect of sacubitril/valsartan (LCZ696) versus valsartan on changes in NT-proBNP and safety and tolerability of in-hospital initiation of

HFpEF (Preserved Ejection Fraction) Patients

Drug Study

Principal Investigator: John Harris, M.D.
Norton Heart & Vascular Institute

Sponsor: Novartis Pharmaceuticals Corp

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.